<DOC>
	<DOCNO>NCT01866709</DOCNO>
	<brief_summary>It hypothesize SPS effective placebo control ( alternative hypothesis ) lower i-STAT potassium level subject i-STAT potassium level 5.0 - 6.5 mmol/l versus difference SPS placebo control ( null hypothesis ) .</brief_summary>
	<brief_title>Safety Efficacy Sodium Polystyrene Sulfonate Hyperkalemia</brief_title>
	<detailed_description>Subjects mild moderate hyperkalemia ( i-STAT potassium level 5.0-6.5 mmol/l , inclusive ) randomize 1:1 double-blind fashion receive placebo SPS ( 15g ) , administer tid meal 48 hour . Subjects come back clinic Study Day 9 End Study ( EOS ) visit . Adverse experience record . Blood potassium level evaluate i-STAT Local Laboratory prior first dose Study Days 1 2 , 1 , 2 , 4 hour first dose Study Day 1 , 1 4 hour first dose Study Day 2 prior breakfast Study Day 3 , 48 hour treatment . Subjects i-STAT potassium level &gt; 6.5 mmol/l Study Day 1 4 hour post Dose 1 time point withdrawn study receive standard care . If i-STAT potassium value 6.1 6.5 mmol/l 4-hour post Dose 1 draw , subject kept clinic another 90 minute post Dose 2 another blood draw take ECG perform . If i-STAT potassium level ≥ 6.2 mmol/l time point , subject discontinue study standard care institute . If i-STAT potassium level &lt; 6.2 mmol/l , ECG show ECG withdrawal criterion ( see ) , subject continue study .</detailed_description>
	<mesh_term>Hyperkalemia</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>Provision write informed consent . Over 18 year age . Mean iSTAT potassium value 5.0 6.5 mmol/l inclusive , screen ( Study Day 0 ) . Previous participation Clinical ZS002 ZS003 protocol ( ) . However , subject enrol study least 30 day elapse last dose study ZS003 . Ability repeat blood draw effective venous catheterization . Women childbearing potential must use two form medically acceptable contraception ( least one barrier method ) negative pregnancy test screening . Women surgically sterile postmenopausal least 2 year consider childbearing potential . Pseudohyperkalemia sign symptom , excessive fist clench hemolyzed blood specimen , severe leukocytosis thrombocytosis . Subjects treat lactulose , Xifaxan nonabsorbed antibiotic hyperammonemia within last 7 day . Subjects treat resin ( Sevelamer acetate ) , calcium acetate , calcium carbonate , lanthanum carbonate , within last 7 day . Subjects treat Sodium Polystyrene Sulfonate ( SPS ; e.g . Kayexalate® ) ZS ( microporous , fractionate , protonated zirconium silicate ) within last 30 day . Subjects life expectancy le 3 month . Subjects HIV positive . Subjects severely physically mentally incapacitated opinion investigator unable perform subject ' task associate protocol . Women pregnant , lactating , plan become pregnant . Subjects diabetic ketoacidosis . Presence condition , opinion investigator , place subject undue risk potentially jeopardize quality data generate . Known hypersensitivity previous anaphylaxis ZS component thereof . Previous treatment SPS . Treatment drug device within last 30 day receive regulatory approval time study entry . Subjects cardiac arrhythmia require immediate treatment . Subjects insulin stable dose yet establish . * Subjects dialysis . * Subjects stable insulin insulin analogue enrol . Subjects insulin dose regimen &gt; 14 day consider stable . Whenever possible , blood draw collect prior meal collect prior insulin/insulin analogue treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>